CD82/KAI1和CD9/MRP-1在神经胶质瘤细胞株中的表达及表达意义的初步研究
摘要
目的胶质瘤是严重危害人类健康的疾病之一,是一种最常见的颅内原发恶性肿瘤。近年来,胶质瘤的发病率和死亡率在国内外均有明显增加,其恶性程度高者预后十分差。胶质瘤细胞本身超乎寻常的局部侵袭、转移能力是疾病治疗过程中所面临的巨大挑战。研究表明,通过对肿瘤转移抑制因子的检测可预判患者预后的情况,甚至可以为胶质瘤的基因治疗提供潜在靶点的理论依据。已有研究表明CD82/KAI1、CD9/MRP-1在众多实体性恶性肿瘤转移和增殖中发挥作用,为进一步研究CD82/KAI1、CD9/MRP-1在胶质瘤细胞发生迁移、增殖中的作用,本文以两种恶性程度存在差异的胶质瘤细胞株(CHG-5、U251)为研究对象,采用细胞培养、免疫细胞化学、PT-PCR等方法从mRNA和蛋白水平初步检测CD82/KAI1、CD9/MRP-1的表达水平,探索其与胶质瘤细胞迁移力和增殖力的关系。
方法1.免疫细胞化学技术分别观察CHG-5、U251中CD82/KAI1、CD9/MRP-1的表达情况;2. RT-PCR分别观察CHG-5、U251中CD82/KAI1mRNA、CD9/MRP-1mRNA的表达情况;3.分别设立1:100、1:200CD82/KAI1抗体干预组和空白对照组,通过划痕试验于24h、48h观察CD82/KAI1对细胞迁移能力的影响并进行统计分析;4.分别设立1:100、1:200、1:400 CD9/MRP-1抗体干预组和空白对照组,通过流式细胞术于24h、48h观察CD9/MRP-1对细胞周期的影响并进行统计分析。
结果1. U251细胞组中CD82/ KAI1及CD9/MRP-1的蛋白水平表达均高于CHG-5细胞组,差异有显著性(P<0.01);2. U251细胞组中CD82/KAI1mRNA及CD9/MRP-1mRNA表达均高于CHG-5细胞组,差异有显著性(P<0.01);3. U251细胞CD82/KAI1抗体干预组迁移细胞数量高于对照组(P<0.05),且迁移细胞数量随抗体浓度升高而增加(P<0.05);4. CHG-5细胞CD9/MRP-1抗体干预组中细胞周期阻滞于G0/G1期,高于对照组(24h:P<0.05;48h:P<0.01),且比例随抗体浓度升高而增加(P<0.05);5. U251细胞CD9/MRP-1抗体干预组中细胞周期阻滞于S期,高于对照组(24h:P<0.01;48h:P<0.01),且比例随抗体浓度升高而呈现上升趋势(P<0.05)。
结论CD82/KAI、CD9/MRP-1均在恶性胶质瘤细胞株中表达,且两者在U251细胞中表达较CHG-5细胞都高;CD82/KAI1可抑制胶质瘤U251细胞的迁移能力,CD9/MRP-1可抑制胶质瘤CHG-5细胞和U251细胞的增殖能力;推测CD82/KAI、CD9/MRP-1的检测能为胶质瘤临床治疗方案的选择和预后的评估提供一定依据。
Objective: Glioma is one of the serious diseases which threat human beings, and one of the most common primary intracranial tumors. In recent years, morbidity and mortality rates of gliomas were significantly increased at home and abroad, their highly malignant and the prognosis are very poor. Glioma cells them exceptional local invasion and metastasis are enormous challenges of the disease course of treatment. Studies have shown that inhibitors of tumor metastasis by testing can predict prognosis of the situation, even for gene therapy of gliomas theoretical basis for potential targets. Studies have also shown that CD82/KAI1, CD9/MRP-1 play important roles in the many entities of tumor metastasis and proliferation. To further study the CD82/KAI1, CD9/MRP-1 in glioma cell migration and proliferation of the role, this paper differ in two malignant glioma cell lines (CHG-5, U251) for the study, using cell culture, immunocytochemistry, PT-PCR methods such as mRNA and protein levels from the initial detection of CD82/KAI1, CD9/ MRP-1 expression, in order to explore the relationship between the ability of tumor cell migration and proliferation and its expression.
Methods: 1. Immunocytochemistry was observed CHG-5, U251 in CD82/KAI1, CD9/MRP-1 expression; 2. RT-PCR was observed CHG-5, U251 in CD82/KAI1mRNA, CD9/MRP-1mRNA expression; 3. 1:100, 1:200 CD82/KAI1 antibody were set up in the intervention group and control group, by wound healing in 24h, 48h observation CD82/KAI1 ability of cell migration and statistical analysis; 4. 1:100, 1:200, 1:400 CD9/MRP-1 antibody were set up in the intervention group and control group, by flow cytometry at 24h, 48h CD9/MRP-1 observed on the cell cycle and statistical analysis.
Results: 1. The expression level of CD82 / KAI1 protein and CD9/MRP-1 protein in U251 cell group was higher than that in CHG-5 cells, the difference was significant (P < 0.01); 2.The expression level of CD82/KAI1mRNA and CD9/MRP-1 mRNA in U251 cell group was higher than that in CHG-5 cells, the difference was significant (P<0.01); 3.The number of migrated cells in U251 cell group which be intervened by CD82/KAI1 antibody were higher than that in their control group (P<0.05), and the number of migrated cells with the antibody concentration increased (P< 0.05); 4. Cell cycle arrest in G0/G1 phase in CHG-5 cell group which be intervened by CD9/MRP-1 antibody, difference compared with the control group(24h:P<0.05;48h:P<0.01), and the proportion increased with antibody concentration(P<0.05); 5. Cell cycle arrest at S phase in U251 cell group which be intervened by CD9/MRP-1 antibody, difference compared with the control group(24h:P<0.01;48h:P<0.01), and the proportion increased with antibody concentration(P<0.05).
Conclusions : CD82/KAI, CD9/MRP-1 expressed in malignant glioma cell lines, and both in U251 cells compared with CHG-5 cells are high;CD82/KAI1 inhibits U251 cell migration, CD9 / MRP-1 can inhibit CHG-5 cells and U251 cell proliferation;We speculate CD82/KAI, CD9/MRP-1 clinical testing will contribute to glioma treatment options and prognosis.
方法1.免疫细胞化学技术分别观察CHG-5、U251中CD82/KAI1、CD9/MRP-1的表达情况;2. RT-PCR分别观察CHG-5、U251中CD82/KAI1mRNA、CD9/MRP-1mRNA的表达情况;3.分别设立1:100、1:200CD82/KAI1抗体干预组和空白对照组,通过划痕试验于24h、48h观察CD82/KAI1对细胞迁移能力的影响并进行统计分析;4.分别设立1:100、1:200、1:400 CD9/MRP-1抗体干预组和空白对照组,通过流式细胞术于24h、48h观察CD9/MRP-1对细胞周期的影响并进行统计分析。
结果1. U251细胞组中CD82/ KAI1及CD9/MRP-1的蛋白水平表达均高于CHG-5细胞组,差异有显著性(P<0.01);2. U251细胞组中CD82/KAI1mRNA及CD9/MRP-1mRNA表达均高于CHG-5细胞组,差异有显著性(P<0.01);3. U251细胞CD82/KAI1抗体干预组迁移细胞数量高于对照组(P<0.05),且迁移细胞数量随抗体浓度升高而增加(P<0.05);4. CHG-5细胞CD9/MRP-1抗体干预组中细胞周期阻滞于G0/G1期,高于对照组(24h:P<0.05;48h:P<0.01),且比例随抗体浓度升高而增加(P<0.05);5. U251细胞CD9/MRP-1抗体干预组中细胞周期阻滞于S期,高于对照组(24h:P<0.01;48h:P<0.01),且比例随抗体浓度升高而呈现上升趋势(P<0.05)。
结论CD82/KAI、CD9/MRP-1均在恶性胶质瘤细胞株中表达,且两者在U251细胞中表达较CHG-5细胞都高;CD82/KAI1可抑制胶质瘤U251细胞的迁移能力,CD9/MRP-1可抑制胶质瘤CHG-5细胞和U251细胞的增殖能力;推测CD82/KAI、CD9/MRP-1的检测能为胶质瘤临床治疗方案的选择和预后的评估提供一定依据。
Objective: Glioma is one of the serious diseases which threat human beings, and one of the most common primary intracranial tumors. In recent years, morbidity and mortality rates of gliomas were significantly increased at home and abroad, their highly malignant and the prognosis are very poor. Glioma cells them exceptional local invasion and metastasis are enormous challenges of the disease course of treatment. Studies have shown that inhibitors of tumor metastasis by testing can predict prognosis of the situation, even for gene therapy of gliomas theoretical basis for potential targets. Studies have also shown that CD82/KAI1, CD9/MRP-1 play important roles in the many entities of tumor metastasis and proliferation. To further study the CD82/KAI1, CD9/MRP-1 in glioma cell migration and proliferation of the role, this paper differ in two malignant glioma cell lines (CHG-5, U251) for the study, using cell culture, immunocytochemistry, PT-PCR methods such as mRNA and protein levels from the initial detection of CD82/KAI1, CD9/ MRP-1 expression, in order to explore the relationship between the ability of tumor cell migration and proliferation and its expression.
Methods: 1. Immunocytochemistry was observed CHG-5, U251 in CD82/KAI1, CD9/MRP-1 expression; 2. RT-PCR was observed CHG-5, U251 in CD82/KAI1mRNA, CD9/MRP-1mRNA expression; 3. 1:100, 1:200 CD82/KAI1 antibody were set up in the intervention group and control group, by wound healing in 24h, 48h observation CD82/KAI1 ability of cell migration and statistical analysis; 4. 1:100, 1:200, 1:400 CD9/MRP-1 antibody were set up in the intervention group and control group, by flow cytometry at 24h, 48h CD9/MRP-1 observed on the cell cycle and statistical analysis.
Results: 1. The expression level of CD82 / KAI1 protein and CD9/MRP-1 protein in U251 cell group was higher than that in CHG-5 cells, the difference was significant (P < 0.01); 2.The expression level of CD82/KAI1mRNA and CD9/MRP-1 mRNA in U251 cell group was higher than that in CHG-5 cells, the difference was significant (P<0.01); 3.The number of migrated cells in U251 cell group which be intervened by CD82/KAI1 antibody were higher than that in their control group (P<0.05), and the number of migrated cells with the antibody concentration increased (P< 0.05); 4. Cell cycle arrest in G0/G1 phase in CHG-5 cell group which be intervened by CD9/MRP-1 antibody, difference compared with the control group(24h:P<0.05;48h:P<0.01), and the proportion increased with antibody concentration(P<0.05); 5. Cell cycle arrest at S phase in U251 cell group which be intervened by CD9/MRP-1 antibody, difference compared with the control group(24h:P<0.01;48h:P<0.01), and the proportion increased with antibody concentration(P<0.05).
Conclusions : CD82/KAI, CD9/MRP-1 expressed in malignant glioma cell lines, and both in U251 cells compared with CHG-5 cells are high;CD82/KAI1 inhibits U251 cell migration, CD9 / MRP-1 can inhibit CHG-5 cells and U251 cell proliferation;We speculate CD82/KAI, CD9/MRP-1 clinical testing will contribute to glioma treatment options and prognosis.
引文
[1]马廉廷.脑胶质瘤治疗的现状与进展[J].中华实验外科杂志,1999,(16):388-389.
[2] Mischel PS, Cloughesy TF, Targeted molecular therapy of GBM [J].Brain Pathol, 2003, 13:52-61.
[3] Brand AA, Rigon A, Zampieri P, et al. Carboplation and teniposide concurrent with radiotherapy in patients glioblastoma multiforme [J].Cancer, 1998, 82(2):355-361.
[4] Kevin C, Tadashi K, Yasuko K, et al.Molecular response of human glioblastoma multiforme cells to ionizing radiation:cell cycle arrest, modulation of the expression of cyclin-dependent kinase inhibitors, and autophagy[J].J Neurosurg, 2003, 98(2):378-384.
[5] Walker DG, Kaye AH.Low grade glial neoplasms[J].Journal of ClinicalNeuroscience, 2003,10(1):1-13.
[6] Sathornsumetee ,SReardon DA,Desjardins A,et a1.Molecularly TargetedTherapy for Malignant Glioma[J]Cancer,2007,11013-24.
[7] Mingjun C,Lin H,Rudong C,et.a1.Inhibition of LRIG3 gene expression via RNA interference modulates the proliferation,cell cycle,cell apoptosis,adhesion andinvasion of glioblastoma cell(GLl5) [J].Cancer Letters,2009,278(1),104-112.
[8] Benjamin Y.S.O,Sudhir H.R,Lai Y L,et.a1.Paclitaxel delivery from PLGA foams for controlled release in post—surgical chemotherapy against glioblastoma multiforme[J].Biomaterials 2009, 30, 3189-3l96.
[9] Engelhard H H, Duncan H A, Dal Canto M. Molecular characterization of glioblastoma cell differentiation [J].Neurosurgery, 1997, 41(4): 886-896.
[10]杜子威,徐庚达,王尧,等.人脑恶性胶质瘤细胞体外长期传代培养的研究[J].江苏医药,1983,3(8): 2-4.
[11] Li P, Zhong XY, Qin YF, et al. Expression of PTEN Gene in Human Glioma Cell Lines U251 and SHG-44 and Its Effect on Cell Proliferation[J].Ai Zheng.2007;26(3): 247-251.
[12]陈自强,卞修武,辛榕,等.人脑胶质瘤细胞系CHG-5的建立及其生物学特性的分析[J].第三军医大学学报,1999,21(12):880-883.
[13] Kovalenko OV,Metcalf DG,DeGrado WF,et a1.Structural organization and interactions of transmembrane domains in tetraspanin proteins [J]BMC Struct Biol,2005,7(28):5-11.
[14] Dong JT,Lamb PW,Rinker CW,et al. KAI1,a metastasis suppressorgene for prostate cancer on human chromosome11p11.2 [J].Science, 1995; 68:884- 886.
[15] Miyake M, Koyama M, Seno M, Ikeyama S.Identification of the Motility- related Protein(MRP-1),recognized by monoclonal antibody M31-15,which inhibits cell motility[J].Exp Med,1991,174:1347-1354.
[16] Ikeyama S,Koyama M, Yamaoko M, et al. Suppression of cell motility and metastasis by transfection with human motility- related protein (MRP-1/CD9) DNA [J].Exp Med, 1993, 177:1231-1237.
[17] Roger Abounader, John Laterra. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis [J]. Neuro-Oncology, 2005, 7(4): 436–51.
[18]李斌,甄海宁,章翔. Notch信号在中枢神经系统肿瘤中的研究进展[J].第四军医大学学报, 2008, 29 (2): 184–86.
[19] Birgit Gellersen, Juliane Briese, Marine Obernd?rfer, et al. Expression of the Meta- stasis Suppressor KAI1 in Decidual Cells at the Human Maternal-Fetal Interface[J]. Am J Pathol, 2007, 170(1):126–139.
[20] Bo He, Li Liu, George A. Cook, et al. Tetraspanin CD82 Attenuates Cellular Morphogenesis through Down-regulating Integrin 6-Mediated Cell Adhesion[J]. THE JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280(5): 3346–3354.
[21] Elika Samandari, Theresa Visarius, Jean-Marc Zingg, et al. The effect of c- tocopherol on proliferation, integrin expression, adhesion, and migration of human glioma cells[J]. Biochemical and Biophysical Research Communications, 2006, 21, 342(4): 1329–1333.
[22] Katrin F?rber, Michael Synowitz, Grit Zahn, et al. Aα5β1 integrin inhibitor attenuates glioma growth [J]. Molecular and Cellular Neuroscience, 2008, 39(4): 579–585.
[23] N. Shastry Akella, Qiang Ding, Ingrid Menegazzo, et al. A novel technique to quantify glioma tumor invasion using serial microscopy sections [J].Journal of Neuroscience Methods, 2006, 153(2): 183–189.
[24] Jee BK, Park KM, Surendran S, et al. KAI1/CD82 suppresses tumor invasion by MMP9 inactivation via TIMP1 up-regulation in the H1299 human lung carcinoma cell line [J]. Biochem Biophys Res Commun, 2006, 342(2): 655-61.
[25] Tobias Martens, Nils-Ole Schmidt, Carmen Eckerich, et al. A Novel One-Armed Anti-c-Met Antibody Inhibits Glioblastoma Growth In vivo[J]. Clinical Cancer Research VO, 2006, 12(20Pt 1): 6144-6152.
[26] Sheng-Hua Chu, Hong Zhang, Yan-Bin Ma, et al. c-Met Antisense Oligodeoxynucleotides as a Novel Therapeutic Agent for Glioma: In Vitro and In Vivo Studies of Uptake, Effects, and Toxicity [J]. Journal of Surgical Research, 2007,141(2): 284–288.
[27] Shenghua Chu, Xianhou Yuan, Zhiqiang Li, et al. C-Met antisense oligodeox- ynucleotide inhibits growth of glioma cells[J]. Surgical Neurology, 2006, 65(6): 533– 538.
[28]尉晓蔚,张倩,谭冬梅,等.重组腺病毒CD82/KAI1对小鼠子宫基质细胞内α5、β3、MMP-9、E-cadherin和β-catenin蛋白表达的影响[J].第三军医大学学报, 2009, 31 (7): 572–576.
[29] Maecker HT, Todd SC, Levy S. The tetraspanin superfamily:molecular facilitators [J].FASEB J 1997 11:428-442.
[30] Hadjiargyrou M, Patterson PH. An anti-CD9 monoclonal antibody promotes adhe- sion and induces proliferation of Schwann cells in vitro[J].J Neurosci 1995 , 15:574-583.
[31] Masellis-Smith A, Shaw AR.CD9-regulated adhesion:anti-CD9 monoclonal antibody induces pre-B cell adhesion to bone marrow fibroblasts through de novo recognition of fibronectin[J].J Immunol 1994152:2768-2777.
[32] Park KR, Inoue T, Ueda M, Hirano T, Higuchi T, Maeda M, Konishi I, Fujiwara H, Fujii S.CD9 is expressed on human endometrial epithelial cells in association withintegrins 6,3 andβ1[J].Mol Hum Reprod 2000 6:252-257.
[33] Ikeyama S, Koyama M, Yamaoko M, Sasada R, Miyake M. Suppression of cell motility and metastasis by transfection with human motility-related protein (MRP/CD9)DNA [J].J Exp Med 1993 177:1231-1237.
[34] Tachibana I, Hemler ME. Role of transmembrane 4 superfamily(TM4SF) proteins CD9 and CD81 in muscle cell fusion and myotube maintenance[J].J Cell Biol 1999 146:893-904.
[35] Oka M, Tagoku K, Russell TL, Nakano Y, Hamazaki T, Meyer EM, Yokota T, Terada N.CD9 is associated with leukemia inhibitory factor-mediated maintenance of embryonic stem cells[J].Mol Biol Cell 2002 13:1274-1281.
[36] Oritani K, Wu X, Medina K, Hudson J, Miyake K, Gimble JM, Burnstein SA, Kincade PW. Antibody ligation of CD9 modifies production of myeloid cells in long-term cultures[J].Blood 1996 87:2252-2261.
[37] Klassen H, Schwartz MR, Bailey AH, Young MJ. Surface markers expressed by multipotent human and mouse progenitor cells include tetraspanins and and non-protein epitopes[J].Neurosci Lett 2001, 312:180-182.
[38] Kanatsu-Shinohara M, Toyokuni S, Shinohara T.CD9 is a surface marker on mouse and rat male germline stem cells[J].Biol Reprod, 2004, 70(1): 70-75.
[39] Kubota H, Avarbock MR, Brinster RL. Spermatogonial stem cells share some,but not all,phenotypic and functional characteristics with other stem cells[J].Proc Natl Acad Sci USA 2003 100:6487-6492.
[40] Nagano M, Patrizio P, Brinster RL. Long-term survival of human spermatogonial stem cells in mouse testes[J].Fertil Steril 2002, 78:1225-1233.
[41] Nakamura Y, Handa K, Iwamoto R, Tsukamoto T, Takahashi M, Mekada E. Immunohistochemical distribution of CD9,heparin binding epidermal growth factor-like growth factor,and integrinβ1 in normal human tissues[J].J Histochem Cytochem 2001, 49:439-444.
[42] Brinster RL, Zimmermann JW. Spermatogenesis following male germ-cell transpl- antation [J].Proc Natl Acad Sci USA 1994, 91:11298-11302.
[43] Clouthier DE, Avarbock MR, Maika SD, Hammer RE, Brinster RL.Rat spermato- genesis in the mouse testis[J].Nature 1996, 381:418-421.
[44] Kagawa T, Mekada E, Shishido Y, Ikenaka K.Immune system-related CD9 is expressed in mouse central nervous system myelin at a very late stage of myelination[J]. J Neurosci Res.1997, 50:312-320.
[45] Nakamura Y, Iwamoto R, Mekada E.Expression and distribution of CD9 in myelin of the central and peripheral nervous systems[J]. Am J Pathol.1996, 149:575-583.
[46] Banerjee SA, Hadjiargyrou M, Patterson PH.An antibody to the tetraspan membrane protein CD9 promotes neurite formation in a partiallyalpha3beta1 integrin- dependent manner[J]. J Neurosci.1997, 17:2756-2765.
[47] Masatou K, Katsumi D, Eisuke M, et a1.CD9 Expression in Solid Non-neuroepi- thelial Tumors and Infiltrative Astrocytic Tumors [J]. J Histochemistry & Cytochemistry. 2002, 50(9), 1195-1203.
[48] Nakamura K, Iwamoto R, Mekada E.Membrane-anchored heparin-binding EGF- like growth factor (HB-EGF) and diphtheria toxin receptor-associated protein (DRAP27)/CD9 form acomplex with integrin alpha3 beta1 atcell-cell contact sites[J]. J Cell Biol.1995, 129:1691-1705.
[49]杨树茂,章翔,费舟,等.人脑胶质瘤组织中cyclin D1和cyclin E表达的研究[J].肿瘤防治杂志. 2004, 11(1),1-3.
[50] Scott K A, Walker R A. Lack of cyclin E immunoreactivity innonmalignant breast and association with proliferation in breast cancer [J]. BrCancer.1997, 76(10), 1288-1292.
[1] Dong JT,Lamb PW,Rinker CW,et al. KAI1,a metastasis suppressor gene for prostate cancer on human chromosome11p11.2 [J].Science,1995,268:884-886.
[2] Dong JT,Suzuki H,Pin SS,et al. Down-regulation of the KAI1Metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene muta- tion or allelic loss [J].Cancer Res,1996;56(19):4387-4390.
[3] Dong JT,Isaacs WB,Barrett JC,et al.Genomic organization of the human KAI1 metastasis suppressor gene[J].Genomics,1997,41:25-32.
[4] Gao AC,Lou W,Dong JT,et al.Defining regulatory elements in the human KAI1/CD82 metastasis suppressor gene [J].Prostate,2003,57(4):256-260.
[5] Kovalenko OV,Metcalf DG,DeGrado WF,et a1.Structural organization and interact- ionsoftransmembrane domains intetraspanin proteins[J].BMCStruct Biol,2005; 7(28): 5-11.
[6] Stipp CS, Kolesnikova TV, Hemler ME.Functional domains in tetraspanin proteins. Trends Biochem[J]. Sci, 2003, 28:106-112.
[7] Horejsi V,Vlcek C,Horejsi V,et a1.Novel structurally distinct family of leucocyte surfaceglycoproteinsincludingCD9,CD37,CD53and CD63[R].FEBS Lett,1991,288: l-4.
[8] Wright MD, Tomlinson MG.The ins and outs of the transmembrane 4 superfamily, Immunol [J].Today, 1994, 15:588-594.
[9] Masciopinto F,Campagnoli S,Abrignani S,et a1.The small extracellular loop of CD- 81 is necessary for optimal surface expression of the large loop,a putmive HCV recapto- r[J].Vir Res.2001.(80):1-10.
[10] TokuharaT, HasegawaH, HattoriN, et a1.Clinical significance of CDl5l gene expression in non-small cell lung cancer[J].ClinCancerRes,2001, 7(11):4109-4114.
[11] Nagira M,Imai T,Ishikawa I,et a1.Mouse homologue of C33 antigen(CD82),a member of the transmembrane4superfamily:complementaryDNA,genomic tructure, and expression[J].Cell Immunol,1994,157:1 44-1 57.
[12] Bouras T, FraumanAG.Expression of the prostate cancer metastasis suppressorgene KAI1 in primary prostate cancers:a biphasic relationship with tumor grade [J ] .J Pathol , 1999,188 (4):382-388.
[13] TomoyukiM,M isakoW,ShigeruH,et al.The expression of KAI1 gene,a tumor metastasis suppressor,is directly activated by P53[J].Proc Natl Acad Sci USA, 1998,95:11307-11311.
[14] JacksonP,MillarD,KingsleyE,et al.Methylationof a CpG island island within the promoter region of the KAIl/CD82 metastasis supplessorgene is not responsible for down,regulation of KAI1/CD82 expression in invasive cancers or cancer cell lines [J].Cancer Lett, 2000,157(21),169-176.
[15] TsutomuS, NaokiN, MasakiH.Transduction of KA11/CD82 cDNA promotes hematogenous spread of human lung cancer cells in natural killer cell- depleted SCID mice [J].Cancer, 2001, 94:238-243.
[16] Lee JH,Seo YW,Park SR,et a1.Expression of a splice variant of KAI1,a tumor metastasis suppressor gene,influences tumor invasion and progression[J].Cancer Res,2003,63:7247-7255.
[17] LeeJH,Park SR,Chay KO,et al.KAI1 COOH-terminal interacting tetraspanin (KITENIN),a member of the tetraspanin family,interacts with KAI1,a tumor metastasis suppressor and enhancesmetastasisofcancer[J].CancerRes,2004,64:4235 -4243.
[18] RoweA, JacksonP. Expression of KITENIN,a KAI1/CD82 binding protein and metastasis enhancer,in bladder cancer cell lines:relationship to KAI 1/CD82 levels and invasive behaviou[J].Oncol Rep, 2006, 16(6):1267-72.
[19] ZhangXA,HeB,ZhouB,et a1.Requirement of the pl30CAS—Crk coupling for metastasis suppressor CD82/KAI 1-mediated inhibition of cell migration[J].J Biol Chem, 2003, 278(9):27319-27328.
[20] Sridhar SC,Miranti CK.Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integfin-dependentcrosstalkwithc-Metreceptor and Src kinases [J].Oncogene,2006,25(16):2367-2378.
[21] JeeB,JinK,HahnJH,et a1.Metastasis-suppressor KAll/CD82 induces homotypicaggregationofhuman prostate cancer cells through Src—dependent pathway[J].Exp Mol Med, 2003, 35(1):30-37.
[22] Mendelsohn J.Targeting the epidermal growth factor receptor for cancer therapy [J]. Clin Oncol, 2002, 20(18 Supp1):1S-13S.
[23] Ciardiello F, Tortora G.A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor [J].Clin Cancer Res, 2001, 7(10):2958-2970.
[24] OdintsovaE,SugiuraT,Berditchevski F.Attenuation of EGF receptor signaling by a metastasissuppressor,thetetraspaninCD82/KAI-1[J].Curt Biol, 2000, l0:1009-1012.
[25] YardenY, Sliwkowski MX, Untangling the ErbB signalling network [J].Nat Rev Mol Cell Biol, 200l, 2:127-137.
[26] OdintsovaE, VoortmanJ, GilbertE, et a1.TetraspaninCD82 regulates compartment- talisationandligand-induceddimerizationofEGFR[J].JCellSci, 2003,116:4557-4566.
[27] WangXQ,Yan Q,Sun P,et a1.Suppression of epidermal growth factor receptor sign- aling by protein kinase C-alpha activation requires CD82,caveolin.1,and ganglioside [J].Cancer Res,2007,67(20):9986-9995.
[28] ZhangXA,LaneWS,CharrinS,et a1.EWl2/PGRL associates with the metastasis suppressor KAI1/CD82 and inhibits the migration of prostate cancer cells[J].Cancer Res, 2003, 63(10):2665-2674.
[29] HumPhries MJ.Integrin structure [J].Biochem Soc Trans, 2000, 28(4):311-339.
[30] MukhopadhyayNK, GordonGJ, ChenCJ, et a1.Activation of focal adhesion kinase in human lung cancer cells involves multiple and potentially parallel signaling events [J].J Cell Mol Med, 2005, 9(2):387-397.
[31] RiemenschneiderMJ,MuellerW,BetenskyRA,et a1.In situ analysis of integrin and growth factor receptor signaling pathways in human glioblastomas suggests overlapping relationships with focal adhesion kinase activation[J].Am J Pathol, 2005,167(5):1379- -1387.
[32] OnoM, HandaK, WithersDA, et a1.Motility inhibition and apoptosis are induced by metastasis-suppressing gene product CD82 and its analogue CD9 with concurrent gly- cosylation [J].Cancer Res, 1999, 59:2335-2339.
[33] 1wataS,Kobayashi H,Miyake-Nishijima R,et a1.Distinctive signaling pathways thr- ough CD82 and betal integrins in human T cells[J],Eur J Immunol,2002,32:1328 -1337.
[34] MannionBA,Berditchevski F,KraeftSK,et a1.Transmembrane-4 superfamily protei- ns CD81(TAPA-1),CD82,CD63,andCD53 specifically associated with integrin alpha4 beta1(CD49d/CD29)[J].Immunol,1996,157:2039-2047.
[35] RoweA, JacksonE. Expression of KITENIN, a KAI1/CD82 binding protein and me- tastasis enhancer, in bladder cancer cell lines: relationship to KAI1/CD82 levels and invasivebehaviou [J].Oncol Rep, 006, 16(6):1267-1272.
[36] FedorB, Elena O.Characterization of integrin-tetraspanin adhesion complexes: role of tetraspanins in integrin signaling [J].Cell Bio, 1999, 146:477-492.
[37] Bas R,Wemer F,Odintsova E,et a1.Regulation of urokinase receptor protelytic func- tion by the tetraspanin CD82[J].Biol Chem,2005,l5,280:14811-14818.
[38] NaotakaS, KenichiH, HironoriY, et a1.Overexpression of CD82 on human T cell enhance LFA-1/ICAM-1 mediated cell-cell adhesion: functional association between CD82 and LFA-l in T cell activation [J].Eur J Immunol, 1999, 29:4081-91.
[39] ZhangXA,BontragerAL,Hemler ME.Transmembrane 4 superfamily proteins associ- ate with activated protein kinase C(PKC)and 1ink PKC to specific betal integrins[J].J Biol Chem,2001,76(27):25005-25013.
[40] DelaquillaumieA,Laqaudriere-Gesbert C,Popoff MR,et a1.Rho GTPases link cyto- skeletal rearrangements and activation processes induced via the tetraspanin CD82 in T lymphocytes[J].J Cell Sci,2002,115(Pt2):433-443.
[41] CecileLG, SophieLB, EmmanuelW, et al.The tetraspaninproteinCD82 associates with both free HLA class I heavy chainand heterodimeric 62-microglobulin complexes [J].Immunol, 1997,158:2790-2797.
[42] UedaT,IchikawaT,Tamani J,et a1.short communication expression of the KAI1 pro- tein in benign prostate hyperplasia and prostate cancer[J].Am J Pathol, 1996, 149:1435- 1440.
[43] WardJM,KonishiN,OhshimaM,et a1.Expression of KAI1 in paraffinembedded nor-mal,hypqplasfic and neoplastic prostate and prostate carcinoma cell lines[J].Pathol Int,1998,48,87-92.
[44] UedaT, IekiY, et a1.Correlation of KAI1/CD82 gene expression with good prognosis in patients with non-small cell lung cancer.Cancer Res, 1996, 56:1751-1755.
[45] MashimoT, WatabeM, HirotaS, et al.The expression of the KAI1 gene, a tumor metastasis suppressor, is directly activated by P53 [J].Proc Natl Acad Sci USA, 1998, 95 (19):11307-11311.
[46] HuWL, LiYQ, HeHX, et a1.KAI1/CD82 gene expression in benign prostatic hyper- plasis and late-stage prostate cancer in Chinese [J].Asian, 2000, 2(3):221.
[47] AdachiM, TakiT, IekiY, et al.Correlation of KAI1/ CD82 gene Expression with good prognosis in patients with non-Small cell lung cancer [J].Cancer Res, 1996, 56 (8): 1751-1755.
[48] HigashiyamaM,KodamaK,YodouchiH,et al.KAI1/ CD82 expression innonsmall cell lung carcinoma is a novel,favorable prognostic factor:an immunohistochemical analy- sis[J].Cancer,1998,83(3):466-474.
[49] TagawaK, ArihiroK, TakeshimaY, et al.Down-regulation of KAI1 messenger RNA expression is not associated with loss of heterozygosity of the KAI1 gene region in lung adenocarcinoma [J].Jpn J Cancer Res, 1999, 90(9):970-976.
[50] SunHC,TangZY,ZhouG,et a1.KAI-1 gene expression in hepatocellular carcinoma and its relationship with intrahepatic metastases[J].Exp Clin Cancer Res,1998,17(3): 307-311.
[51]张捷,陈晓华.KAI1在原发性肝癌组织中的表达水平及调控机制的初探[J].中国实验诊断学,2003,7(3)234-237.
[52] ZhangWG,WangY,ChenH,et a1.The Significance of Transmembrane 4 Super Families(TM4SF)Express in Human Hepatocellular Carcinoma(HCC)[J].Chin J Cli Me- d Pra,2004,3(3):197-l99.Chinese.
[53]彭志红,唐波,杨建民,等.KAI1基因对MHCC97-H肝癌细胞粘附力的影响[J].第三军医大学学报,2005,27(23):2311-2313.
[54]杨建民,司遂海,彭志红,等.KAI1基因对肝癌细胞侵袭、转移的影响及其分子机制[J].浙江医学,2005,27(12)891-895.
[55] TsutsumiS, ShimuraT, MorinagaN, et al.Loss of KAI1 expression in gastric cancer [J]. Hepato-Gastroenterology, 2005, 52(61), 281-284.
[56] YuY, YangJL, MarkovicB, et al.Loss of KAI1 messenger RNA expression on both high-grade and invasive human bladder cancers [J].Clin Cancer Res, 1997, 3(7): 1045– 1049.
[57] GeradtsJ, MaynardR, BirnerMJ, et a1.Frequent loss of KAI1/CD82 expression in squamous and Lymphoid neoplasms [J].Am J Pathol, 1999, 154(6):1665-1671.
[58] SehindlM, BirnerP, BachtiaryB, et aL.The impact of expression of the metastasis suppressor protein KAI1/CD82 on prognosis in invasive squamous cell cervical cancer [J].Anticancer Res, 2000, 20(6b):4551-4556.
[59] Sehindl M,Bachtiary B,Dreier B,et al.Impact of human papillomavirus infection on the expression of the KAI1/CD82 metastasis suppressor protein invasion cervical cancer [J].Cancer Lett,2001,162(2),261-266.
[60] Lie FS,Chen JT,Dong JT,et a1.KAI1 metastasis suppressor gene is frequently down regulated in Cervical carcinoma [J].Am J Padloi,2001,159(5):1629-1634.
[61] Sehindl M,Bachtiary B,Dreier B,et al.Impact of human papillomavirus infection on the expression of the KAI1/CD82 metastasis suppressor protein invasion cervical cance- r[J].Cancer Lett.2001.162(2):261-266.
[62]王国庆,李明众,刘孜.KAI1/CD82、E-cadherin在宫颈鳞癌组织中的表达及意义[J].西安交通大学学报,2006,3(27): 274-277.
[63] WhiteA,LambPW,BarrettJC,et a1,Frequent down regulation of the KAI1(CD82) metastasissuppressorproteininhumancancercell lines[J].Oncogene,1998,16:3143-31 49.
[64] LiuFS, Dong JT, ChenJT, et a1.Frequent down-regulation and lack of mutation of the KAI1/CD82 metastasis suppressor gene in epithelial ovarian carcinoma [J]. Gynecol Oncol, 2000, 78(1):10-15.
[65] SchindlM, BimerP, BreiteneckerG, et a1.Down regulation of KAI1/CD82metastasis suppressor protein is associated with a dismal prognosis in epithelial ovarian cancer [J]. Gynecol Oncol, 2001, 83(2):244-248.
[66] Houle CD, Ding XY, Foley JF, et a1.Loss of expression and altered localization of KAI1/CD82and CD9 protein are associated with epithelial ovarian cancer progression. [J].Gynecologyic Onco1ogy, 2002, 86:69-78.
[67] Guo XZ, Friess H, Maurer C, et al.KAI1 is unchanged in metastatic and nonmetast- atic esophageal and gastric cancers [J]. Cancer Res, 1998, 58(4): 753-758.
[68] HinodaY,AdachiY,Takaoka A,et a1.Decreased expression of the metastasis supper- ssor gene KAI1in gastric cancer[J].Cancer letters,1998,129:229-234.
[69] MiyazakiT,KatoH,ShitaraY,et a1.Mutation and expression of KAI1 the metastasis suppressor gene KAI1 in esophageal squamous cell carcinoma [J].Cancer, 2000. 89(5): 955-962.
[70] Zheng HC,Wang MC,Li JY,et a1.Expression of maspin and kai 1 and their clinic- pathological significance in carcinogenesis and progression of gastric cancer [J]. Chin Med Sci J,2004,19(3):193-198.
[71] Ji RY,Shen Y,Wang CH,et a1Relationship of the expression of KAI1/CD82 and lymph nodes metastases in esophageal cancer[J].The Preatical Journal of Cancer,2004,19(4):379-381,Chinese.
[72] Tsutsumi S,Shimura T,Morinaga N,et a1.Loss of KAI1 expression in gastric cancer[J] Hepatogastroenterology,2005,52(61):281-284.
[73] Aryee ND,Ambros I,Ambros PF,et al. Frequent low level expression in Ewing Sarcoma family tumors and wide spread absence of the metastasis suppressor KAll/CD82 in neuroblastoma[J].. Pediatr Res.2002:52(2):279-85.
[74]宋华,董祷,吕振华等.KAll/CD82在神经母细胞瘤转移中的表达及意义.中华小儿外科杂志,2007,28(8):429-432.
[2] Mischel PS, Cloughesy TF, Targeted molecular therapy of GBM [J].Brain Pathol, 2003, 13:52-61.
[3] Brand AA, Rigon A, Zampieri P, et al. Carboplation and teniposide concurrent with radiotherapy in patients glioblastoma multiforme [J].Cancer, 1998, 82(2):355-361.
[4] Kevin C, Tadashi K, Yasuko K, et al.Molecular response of human glioblastoma multiforme cells to ionizing radiation:cell cycle arrest, modulation of the expression of cyclin-dependent kinase inhibitors, and autophagy[J].J Neurosurg, 2003, 98(2):378-384.
[5] Walker DG, Kaye AH.Low grade glial neoplasms[J].Journal of ClinicalNeuroscience, 2003,10(1):1-13.
[6] Sathornsumetee ,SReardon DA,Desjardins A,et a1.Molecularly TargetedTherapy for Malignant Glioma[J]Cancer,2007,11013-24.
[7] Mingjun C,Lin H,Rudong C,et.a1.Inhibition of LRIG3 gene expression via RNA interference modulates the proliferation,cell cycle,cell apoptosis,adhesion andinvasion of glioblastoma cell(GLl5) [J].Cancer Letters,2009,278(1),104-112.
[8] Benjamin Y.S.O,Sudhir H.R,Lai Y L,et.a1.Paclitaxel delivery from PLGA foams for controlled release in post—surgical chemotherapy against glioblastoma multiforme[J].Biomaterials 2009, 30, 3189-3l96.
[9] Engelhard H H, Duncan H A, Dal Canto M. Molecular characterization of glioblastoma cell differentiation [J].Neurosurgery, 1997, 41(4): 886-896.
[10]杜子威,徐庚达,王尧,等.人脑恶性胶质瘤细胞体外长期传代培养的研究[J].江苏医药,1983,3(8): 2-4.
[11] Li P, Zhong XY, Qin YF, et al. Expression of PTEN Gene in Human Glioma Cell Lines U251 and SHG-44 and Its Effect on Cell Proliferation[J].Ai Zheng.2007;26(3): 247-251.
[12]陈自强,卞修武,辛榕,等.人脑胶质瘤细胞系CHG-5的建立及其生物学特性的分析[J].第三军医大学学报,1999,21(12):880-883.
[13] Kovalenko OV,Metcalf DG,DeGrado WF,et a1.Structural organization and interactions of transmembrane domains in tetraspanin proteins [J]BMC Struct Biol,2005,7(28):5-11.
[14] Dong JT,Lamb PW,Rinker CW,et al. KAI1,a metastasis suppressorgene for prostate cancer on human chromosome11p11.2 [J].Science, 1995; 68:884- 886.
[15] Miyake M, Koyama M, Seno M, Ikeyama S.Identification of the Motility- related Protein(MRP-1),recognized by monoclonal antibody M31-15,which inhibits cell motility[J].Exp Med,1991,174:1347-1354.
[16] Ikeyama S,Koyama M, Yamaoko M, et al. Suppression of cell motility and metastasis by transfection with human motility- related protein (MRP-1/CD9) DNA [J].Exp Med, 1993, 177:1231-1237.
[17] Roger Abounader, John Laterra. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis [J]. Neuro-Oncology, 2005, 7(4): 436–51.
[18]李斌,甄海宁,章翔. Notch信号在中枢神经系统肿瘤中的研究进展[J].第四军医大学学报, 2008, 29 (2): 184–86.
[19] Birgit Gellersen, Juliane Briese, Marine Obernd?rfer, et al. Expression of the Meta- stasis Suppressor KAI1 in Decidual Cells at the Human Maternal-Fetal Interface[J]. Am J Pathol, 2007, 170(1):126–139.
[20] Bo He, Li Liu, George A. Cook, et al. Tetraspanin CD82 Attenuates Cellular Morphogenesis through Down-regulating Integrin 6-Mediated Cell Adhesion[J]. THE JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280(5): 3346–3354.
[21] Elika Samandari, Theresa Visarius, Jean-Marc Zingg, et al. The effect of c- tocopherol on proliferation, integrin expression, adhesion, and migration of human glioma cells[J]. Biochemical and Biophysical Research Communications, 2006, 21, 342(4): 1329–1333.
[22] Katrin F?rber, Michael Synowitz, Grit Zahn, et al. Aα5β1 integrin inhibitor attenuates glioma growth [J]. Molecular and Cellular Neuroscience, 2008, 39(4): 579–585.
[23] N. Shastry Akella, Qiang Ding, Ingrid Menegazzo, et al. A novel technique to quantify glioma tumor invasion using serial microscopy sections [J].Journal of Neuroscience Methods, 2006, 153(2): 183–189.
[24] Jee BK, Park KM, Surendran S, et al. KAI1/CD82 suppresses tumor invasion by MMP9 inactivation via TIMP1 up-regulation in the H1299 human lung carcinoma cell line [J]. Biochem Biophys Res Commun, 2006, 342(2): 655-61.
[25] Tobias Martens, Nils-Ole Schmidt, Carmen Eckerich, et al. A Novel One-Armed Anti-c-Met Antibody Inhibits Glioblastoma Growth In vivo[J]. Clinical Cancer Research VO, 2006, 12(20Pt 1): 6144-6152.
[26] Sheng-Hua Chu, Hong Zhang, Yan-Bin Ma, et al. c-Met Antisense Oligodeoxynucleotides as a Novel Therapeutic Agent for Glioma: In Vitro and In Vivo Studies of Uptake, Effects, and Toxicity [J]. Journal of Surgical Research, 2007,141(2): 284–288.
[27] Shenghua Chu, Xianhou Yuan, Zhiqiang Li, et al. C-Met antisense oligodeox- ynucleotide inhibits growth of glioma cells[J]. Surgical Neurology, 2006, 65(6): 533– 538.
[28]尉晓蔚,张倩,谭冬梅,等.重组腺病毒CD82/KAI1对小鼠子宫基质细胞内α5、β3、MMP-9、E-cadherin和β-catenin蛋白表达的影响[J].第三军医大学学报, 2009, 31 (7): 572–576.
[29] Maecker HT, Todd SC, Levy S. The tetraspanin superfamily:molecular facilitators [J].FASEB J 1997 11:428-442.
[30] Hadjiargyrou M, Patterson PH. An anti-CD9 monoclonal antibody promotes adhe- sion and induces proliferation of Schwann cells in vitro[J].J Neurosci 1995 , 15:574-583.
[31] Masellis-Smith A, Shaw AR.CD9-regulated adhesion:anti-CD9 monoclonal antibody induces pre-B cell adhesion to bone marrow fibroblasts through de novo recognition of fibronectin[J].J Immunol 1994152:2768-2777.
[32] Park KR, Inoue T, Ueda M, Hirano T, Higuchi T, Maeda M, Konishi I, Fujiwara H, Fujii S.CD9 is expressed on human endometrial epithelial cells in association withintegrins 6,3 andβ1[J].Mol Hum Reprod 2000 6:252-257.
[33] Ikeyama S, Koyama M, Yamaoko M, Sasada R, Miyake M. Suppression of cell motility and metastasis by transfection with human motility-related protein (MRP/CD9)DNA [J].J Exp Med 1993 177:1231-1237.
[34] Tachibana I, Hemler ME. Role of transmembrane 4 superfamily(TM4SF) proteins CD9 and CD81 in muscle cell fusion and myotube maintenance[J].J Cell Biol 1999 146:893-904.
[35] Oka M, Tagoku K, Russell TL, Nakano Y, Hamazaki T, Meyer EM, Yokota T, Terada N.CD9 is associated with leukemia inhibitory factor-mediated maintenance of embryonic stem cells[J].Mol Biol Cell 2002 13:1274-1281.
[36] Oritani K, Wu X, Medina K, Hudson J, Miyake K, Gimble JM, Burnstein SA, Kincade PW. Antibody ligation of CD9 modifies production of myeloid cells in long-term cultures[J].Blood 1996 87:2252-2261.
[37] Klassen H, Schwartz MR, Bailey AH, Young MJ. Surface markers expressed by multipotent human and mouse progenitor cells include tetraspanins and and non-protein epitopes[J].Neurosci Lett 2001, 312:180-182.
[38] Kanatsu-Shinohara M, Toyokuni S, Shinohara T.CD9 is a surface marker on mouse and rat male germline stem cells[J].Biol Reprod, 2004, 70(1): 70-75.
[39] Kubota H, Avarbock MR, Brinster RL. Spermatogonial stem cells share some,but not all,phenotypic and functional characteristics with other stem cells[J].Proc Natl Acad Sci USA 2003 100:6487-6492.
[40] Nagano M, Patrizio P, Brinster RL. Long-term survival of human spermatogonial stem cells in mouse testes[J].Fertil Steril 2002, 78:1225-1233.
[41] Nakamura Y, Handa K, Iwamoto R, Tsukamoto T, Takahashi M, Mekada E. Immunohistochemical distribution of CD9,heparin binding epidermal growth factor-like growth factor,and integrinβ1 in normal human tissues[J].J Histochem Cytochem 2001, 49:439-444.
[42] Brinster RL, Zimmermann JW. Spermatogenesis following male germ-cell transpl- antation [J].Proc Natl Acad Sci USA 1994, 91:11298-11302.
[43] Clouthier DE, Avarbock MR, Maika SD, Hammer RE, Brinster RL.Rat spermato- genesis in the mouse testis[J].Nature 1996, 381:418-421.
[44] Kagawa T, Mekada E, Shishido Y, Ikenaka K.Immune system-related CD9 is expressed in mouse central nervous system myelin at a very late stage of myelination[J]. J Neurosci Res.1997, 50:312-320.
[45] Nakamura Y, Iwamoto R, Mekada E.Expression and distribution of CD9 in myelin of the central and peripheral nervous systems[J]. Am J Pathol.1996, 149:575-583.
[46] Banerjee SA, Hadjiargyrou M, Patterson PH.An antibody to the tetraspan membrane protein CD9 promotes neurite formation in a partiallyalpha3beta1 integrin- dependent manner[J]. J Neurosci.1997, 17:2756-2765.
[47] Masatou K, Katsumi D, Eisuke M, et a1.CD9 Expression in Solid Non-neuroepi- thelial Tumors and Infiltrative Astrocytic Tumors [J]. J Histochemistry & Cytochemistry. 2002, 50(9), 1195-1203.
[48] Nakamura K, Iwamoto R, Mekada E.Membrane-anchored heparin-binding EGF- like growth factor (HB-EGF) and diphtheria toxin receptor-associated protein (DRAP27)/CD9 form acomplex with integrin alpha3 beta1 atcell-cell contact sites[J]. J Cell Biol.1995, 129:1691-1705.
[49]杨树茂,章翔,费舟,等.人脑胶质瘤组织中cyclin D1和cyclin E表达的研究[J].肿瘤防治杂志. 2004, 11(1),1-3.
[50] Scott K A, Walker R A. Lack of cyclin E immunoreactivity innonmalignant breast and association with proliferation in breast cancer [J]. BrCancer.1997, 76(10), 1288-1292.
[1] Dong JT,Lamb PW,Rinker CW,et al. KAI1,a metastasis suppressor gene for prostate cancer on human chromosome11p11.2 [J].Science,1995,268:884-886.
[2] Dong JT,Suzuki H,Pin SS,et al. Down-regulation of the KAI1Metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene muta- tion or allelic loss [J].Cancer Res,1996;56(19):4387-4390.
[3] Dong JT,Isaacs WB,Barrett JC,et al.Genomic organization of the human KAI1 metastasis suppressor gene[J].Genomics,1997,41:25-32.
[4] Gao AC,Lou W,Dong JT,et al.Defining regulatory elements in the human KAI1/CD82 metastasis suppressor gene [J].Prostate,2003,57(4):256-260.
[5] Kovalenko OV,Metcalf DG,DeGrado WF,et a1.Structural organization and interact- ionsoftransmembrane domains intetraspanin proteins[J].BMCStruct Biol,2005; 7(28): 5-11.
[6] Stipp CS, Kolesnikova TV, Hemler ME.Functional domains in tetraspanin proteins. Trends Biochem[J]. Sci, 2003, 28:106-112.
[7] Horejsi V,Vlcek C,Horejsi V,et a1.Novel structurally distinct family of leucocyte surfaceglycoproteinsincludingCD9,CD37,CD53and CD63[R].FEBS Lett,1991,288: l-4.
[8] Wright MD, Tomlinson MG.The ins and outs of the transmembrane 4 superfamily, Immunol [J].Today, 1994, 15:588-594.
[9] Masciopinto F,Campagnoli S,Abrignani S,et a1.The small extracellular loop of CD- 81 is necessary for optimal surface expression of the large loop,a putmive HCV recapto- r[J].Vir Res.2001.(80):1-10.
[10] TokuharaT, HasegawaH, HattoriN, et a1.Clinical significance of CDl5l gene expression in non-small cell lung cancer[J].ClinCancerRes,2001, 7(11):4109-4114.
[11] Nagira M,Imai T,Ishikawa I,et a1.Mouse homologue of C33 antigen(CD82),a member of the transmembrane4superfamily:complementaryDNA,genomic tructure, and expression[J].Cell Immunol,1994,157:1 44-1 57.
[12] Bouras T, FraumanAG.Expression of the prostate cancer metastasis suppressorgene KAI1 in primary prostate cancers:a biphasic relationship with tumor grade [J ] .J Pathol , 1999,188 (4):382-388.
[13] TomoyukiM,M isakoW,ShigeruH,et al.The expression of KAI1 gene,a tumor metastasis suppressor,is directly activated by P53[J].Proc Natl Acad Sci USA, 1998,95:11307-11311.
[14] JacksonP,MillarD,KingsleyE,et al.Methylationof a CpG island island within the promoter region of the KAIl/CD82 metastasis supplessorgene is not responsible for down,regulation of KAI1/CD82 expression in invasive cancers or cancer cell lines [J].Cancer Lett, 2000,157(21),169-176.
[15] TsutomuS, NaokiN, MasakiH.Transduction of KA11/CD82 cDNA promotes hematogenous spread of human lung cancer cells in natural killer cell- depleted SCID mice [J].Cancer, 2001, 94:238-243.
[16] Lee JH,Seo YW,Park SR,et a1.Expression of a splice variant of KAI1,a tumor metastasis suppressor gene,influences tumor invasion and progression[J].Cancer Res,2003,63:7247-7255.
[17] LeeJH,Park SR,Chay KO,et al.KAI1 COOH-terminal interacting tetraspanin (KITENIN),a member of the tetraspanin family,interacts with KAI1,a tumor metastasis suppressor and enhancesmetastasisofcancer[J].CancerRes,2004,64:4235 -4243.
[18] RoweA, JacksonP. Expression of KITENIN,a KAI1/CD82 binding protein and metastasis enhancer,in bladder cancer cell lines:relationship to KAI 1/CD82 levels and invasive behaviou[J].Oncol Rep, 2006, 16(6):1267-72.
[19] ZhangXA,HeB,ZhouB,et a1.Requirement of the pl30CAS—Crk coupling for metastasis suppressor CD82/KAI 1-mediated inhibition of cell migration[J].J Biol Chem, 2003, 278(9):27319-27328.
[20] Sridhar SC,Miranti CK.Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integfin-dependentcrosstalkwithc-Metreceptor and Src kinases [J].Oncogene,2006,25(16):2367-2378.
[21] JeeB,JinK,HahnJH,et a1.Metastasis-suppressor KAll/CD82 induces homotypicaggregationofhuman prostate cancer cells through Src—dependent pathway[J].Exp Mol Med, 2003, 35(1):30-37.
[22] Mendelsohn J.Targeting the epidermal growth factor receptor for cancer therapy [J]. Clin Oncol, 2002, 20(18 Supp1):1S-13S.
[23] Ciardiello F, Tortora G.A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor [J].Clin Cancer Res, 2001, 7(10):2958-2970.
[24] OdintsovaE,SugiuraT,Berditchevski F.Attenuation of EGF receptor signaling by a metastasissuppressor,thetetraspaninCD82/KAI-1[J].Curt Biol, 2000, l0:1009-1012.
[25] YardenY, Sliwkowski MX, Untangling the ErbB signalling network [J].Nat Rev Mol Cell Biol, 200l, 2:127-137.
[26] OdintsovaE, VoortmanJ, GilbertE, et a1.TetraspaninCD82 regulates compartment- talisationandligand-induceddimerizationofEGFR[J].JCellSci, 2003,116:4557-4566.
[27] WangXQ,Yan Q,Sun P,et a1.Suppression of epidermal growth factor receptor sign- aling by protein kinase C-alpha activation requires CD82,caveolin.1,and ganglioside [J].Cancer Res,2007,67(20):9986-9995.
[28] ZhangXA,LaneWS,CharrinS,et a1.EWl2/PGRL associates with the metastasis suppressor KAI1/CD82 and inhibits the migration of prostate cancer cells[J].Cancer Res, 2003, 63(10):2665-2674.
[29] HumPhries MJ.Integrin structure [J].Biochem Soc Trans, 2000, 28(4):311-339.
[30] MukhopadhyayNK, GordonGJ, ChenCJ, et a1.Activation of focal adhesion kinase in human lung cancer cells involves multiple and potentially parallel signaling events [J].J Cell Mol Med, 2005, 9(2):387-397.
[31] RiemenschneiderMJ,MuellerW,BetenskyRA,et a1.In situ analysis of integrin and growth factor receptor signaling pathways in human glioblastomas suggests overlapping relationships with focal adhesion kinase activation[J].Am J Pathol, 2005,167(5):1379- -1387.
[32] OnoM, HandaK, WithersDA, et a1.Motility inhibition and apoptosis are induced by metastasis-suppressing gene product CD82 and its analogue CD9 with concurrent gly- cosylation [J].Cancer Res, 1999, 59:2335-2339.
[33] 1wataS,Kobayashi H,Miyake-Nishijima R,et a1.Distinctive signaling pathways thr- ough CD82 and betal integrins in human T cells[J],Eur J Immunol,2002,32:1328 -1337.
[34] MannionBA,Berditchevski F,KraeftSK,et a1.Transmembrane-4 superfamily protei- ns CD81(TAPA-1),CD82,CD63,andCD53 specifically associated with integrin alpha4 beta1(CD49d/CD29)[J].Immunol,1996,157:2039-2047.
[35] RoweA, JacksonE. Expression of KITENIN, a KAI1/CD82 binding protein and me- tastasis enhancer, in bladder cancer cell lines: relationship to KAI1/CD82 levels and invasivebehaviou [J].Oncol Rep, 006, 16(6):1267-1272.
[36] FedorB, Elena O.Characterization of integrin-tetraspanin adhesion complexes: role of tetraspanins in integrin signaling [J].Cell Bio, 1999, 146:477-492.
[37] Bas R,Wemer F,Odintsova E,et a1.Regulation of urokinase receptor protelytic func- tion by the tetraspanin CD82[J].Biol Chem,2005,l5,280:14811-14818.
[38] NaotakaS, KenichiH, HironoriY, et a1.Overexpression of CD82 on human T cell enhance LFA-1/ICAM-1 mediated cell-cell adhesion: functional association between CD82 and LFA-l in T cell activation [J].Eur J Immunol, 1999, 29:4081-91.
[39] ZhangXA,BontragerAL,Hemler ME.Transmembrane 4 superfamily proteins associ- ate with activated protein kinase C(PKC)and 1ink PKC to specific betal integrins[J].J Biol Chem,2001,76(27):25005-25013.
[40] DelaquillaumieA,Laqaudriere-Gesbert C,Popoff MR,et a1.Rho GTPases link cyto- skeletal rearrangements and activation processes induced via the tetraspanin CD82 in T lymphocytes[J].J Cell Sci,2002,115(Pt2):433-443.
[41] CecileLG, SophieLB, EmmanuelW, et al.The tetraspaninproteinCD82 associates with both free HLA class I heavy chainand heterodimeric 62-microglobulin complexes [J].Immunol, 1997,158:2790-2797.
[42] UedaT,IchikawaT,Tamani J,et a1.short communication expression of the KAI1 pro- tein in benign prostate hyperplasia and prostate cancer[J].Am J Pathol, 1996, 149:1435- 1440.
[43] WardJM,KonishiN,OhshimaM,et a1.Expression of KAI1 in paraffinembedded nor-mal,hypqplasfic and neoplastic prostate and prostate carcinoma cell lines[J].Pathol Int,1998,48,87-92.
[44] UedaT, IekiY, et a1.Correlation of KAI1/CD82 gene expression with good prognosis in patients with non-small cell lung cancer.Cancer Res, 1996, 56:1751-1755.
[45] MashimoT, WatabeM, HirotaS, et al.The expression of the KAI1 gene, a tumor metastasis suppressor, is directly activated by P53 [J].Proc Natl Acad Sci USA, 1998, 95 (19):11307-11311.
[46] HuWL, LiYQ, HeHX, et a1.KAI1/CD82 gene expression in benign prostatic hyper- plasis and late-stage prostate cancer in Chinese [J].Asian, 2000, 2(3):221.
[47] AdachiM, TakiT, IekiY, et al.Correlation of KAI1/ CD82 gene Expression with good prognosis in patients with non-Small cell lung cancer [J].Cancer Res, 1996, 56 (8): 1751-1755.
[48] HigashiyamaM,KodamaK,YodouchiH,et al.KAI1/ CD82 expression innonsmall cell lung carcinoma is a novel,favorable prognostic factor:an immunohistochemical analy- sis[J].Cancer,1998,83(3):466-474.
[49] TagawaK, ArihiroK, TakeshimaY, et al.Down-regulation of KAI1 messenger RNA expression is not associated with loss of heterozygosity of the KAI1 gene region in lung adenocarcinoma [J].Jpn J Cancer Res, 1999, 90(9):970-976.
[50] SunHC,TangZY,ZhouG,et a1.KAI-1 gene expression in hepatocellular carcinoma and its relationship with intrahepatic metastases[J].Exp Clin Cancer Res,1998,17(3): 307-311.
[51]张捷,陈晓华.KAI1在原发性肝癌组织中的表达水平及调控机制的初探[J].中国实验诊断学,2003,7(3)234-237.
[52] ZhangWG,WangY,ChenH,et a1.The Significance of Transmembrane 4 Super Families(TM4SF)Express in Human Hepatocellular Carcinoma(HCC)[J].Chin J Cli Me- d Pra,2004,3(3):197-l99.Chinese.
[53]彭志红,唐波,杨建民,等.KAI1基因对MHCC97-H肝癌细胞粘附力的影响[J].第三军医大学学报,2005,27(23):2311-2313.
[54]杨建民,司遂海,彭志红,等.KAI1基因对肝癌细胞侵袭、转移的影响及其分子机制[J].浙江医学,2005,27(12)891-895.
[55] TsutsumiS, ShimuraT, MorinagaN, et al.Loss of KAI1 expression in gastric cancer [J]. Hepato-Gastroenterology, 2005, 52(61), 281-284.
[56] YuY, YangJL, MarkovicB, et al.Loss of KAI1 messenger RNA expression on both high-grade and invasive human bladder cancers [J].Clin Cancer Res, 1997, 3(7): 1045– 1049.
[57] GeradtsJ, MaynardR, BirnerMJ, et a1.Frequent loss of KAI1/CD82 expression in squamous and Lymphoid neoplasms [J].Am J Pathol, 1999, 154(6):1665-1671.
[58] SehindlM, BirnerP, BachtiaryB, et aL.The impact of expression of the metastasis suppressor protein KAI1/CD82 on prognosis in invasive squamous cell cervical cancer [J].Anticancer Res, 2000, 20(6b):4551-4556.
[59] Sehindl M,Bachtiary B,Dreier B,et al.Impact of human papillomavirus infection on the expression of the KAI1/CD82 metastasis suppressor protein invasion cervical cancer [J].Cancer Lett,2001,162(2),261-266.
[60] Lie FS,Chen JT,Dong JT,et a1.KAI1 metastasis suppressor gene is frequently down regulated in Cervical carcinoma [J].Am J Padloi,2001,159(5):1629-1634.
[61] Sehindl M,Bachtiary B,Dreier B,et al.Impact of human papillomavirus infection on the expression of the KAI1/CD82 metastasis suppressor protein invasion cervical cance- r[J].Cancer Lett.2001.162(2):261-266.
[62]王国庆,李明众,刘孜.KAI1/CD82、E-cadherin在宫颈鳞癌组织中的表达及意义[J].西安交通大学学报,2006,3(27): 274-277.
[63] WhiteA,LambPW,BarrettJC,et a1,Frequent down regulation of the KAI1(CD82) metastasissuppressorproteininhumancancercell lines[J].Oncogene,1998,16:3143-31 49.
[64] LiuFS, Dong JT, ChenJT, et a1.Frequent down-regulation and lack of mutation of the KAI1/CD82 metastasis suppressor gene in epithelial ovarian carcinoma [J]. Gynecol Oncol, 2000, 78(1):10-15.
[65] SchindlM, BimerP, BreiteneckerG, et a1.Down regulation of KAI1/CD82metastasis suppressor protein is associated with a dismal prognosis in epithelial ovarian cancer [J]. Gynecol Oncol, 2001, 83(2):244-248.
[66] Houle CD, Ding XY, Foley JF, et a1.Loss of expression and altered localization of KAI1/CD82and CD9 protein are associated with epithelial ovarian cancer progression. [J].Gynecologyic Onco1ogy, 2002, 86:69-78.
[67] Guo XZ, Friess H, Maurer C, et al.KAI1 is unchanged in metastatic and nonmetast- atic esophageal and gastric cancers [J]. Cancer Res, 1998, 58(4): 753-758.
[68] HinodaY,AdachiY,Takaoka A,et a1.Decreased expression of the metastasis supper- ssor gene KAI1in gastric cancer[J].Cancer letters,1998,129:229-234.
[69] MiyazakiT,KatoH,ShitaraY,et a1.Mutation and expression of KAI1 the metastasis suppressor gene KAI1 in esophageal squamous cell carcinoma [J].Cancer, 2000. 89(5): 955-962.
[70] Zheng HC,Wang MC,Li JY,et a1.Expression of maspin and kai 1 and their clinic- pathological significance in carcinogenesis and progression of gastric cancer [J]. Chin Med Sci J,2004,19(3):193-198.
[71] Ji RY,Shen Y,Wang CH,et a1Relationship of the expression of KAI1/CD82 and lymph nodes metastases in esophageal cancer[J].The Preatical Journal of Cancer,2004,19(4):379-381,Chinese.
[72] Tsutsumi S,Shimura T,Morinaga N,et a1.Loss of KAI1 expression in gastric cancer[J] Hepatogastroenterology,2005,52(61):281-284.
[73] Aryee ND,Ambros I,Ambros PF,et al. Frequent low level expression in Ewing Sarcoma family tumors and wide spread absence of the metastasis suppressor KAll/CD82 in neuroblastoma[J].. Pediatr Res.2002:52(2):279-85.
[74]宋华,董祷,吕振华等.KAll/CD82在神经母细胞瘤转移中的表达及意义.中华小儿外科杂志,2007,28(8):429-432.